Trilaciclib Dihydrochloride Dihydrate is a transient cyclin-dependent kinase 4/6 (CDK4/6) inhibitor primarily used to reduce chemotherapy-induced myelosuppression in patients undergoing treatment for extensive-stage… Read more
Trilaciclib Dihydrochloride Dihydrate is a transient cyclin-dependent kinase 4/6 (CDK4/6) inhibitor primarily used to reduce chemotherapy-induced myelosuppression in patients undergoing treatment for extensive-stage small-cell lung cancer. As an essential myeloprotective agent, this compound helps protect bone marrow cells from the toxic effects of platinum-based chemotherapy and etoposide regimens. The category includes reference standards, potential process-related impurities, related metabolites, and stable isotope-labelled compounds required for the rigorous analytical testing and quality control of this active pharmaceutical ingredient. Laboratories utilize these high-quality materials for impurity profiling, method validation, and precise quantification during stability studies. By providing accurate benchmarks, these standards ensure the reliability and safety of the pharmaceutical product throughout its development and manufacturing lifecycle, supporting compliance with regulatory standards for therapeutic consistency.